Oncology Data Advisor is excited to be launching our new podcast series, "Exploring Artificial Intelligence in Oncology." Hosted by Waqas Haque, MD, MPH, Member of the Oncology Data Advisor Fellows Forum, this series will delve into the burgeoning roles and uses of AI in cancer care, from pathology to toxicity risk prediction to treatment recommendations and beyond.

Exploring Artificial Intelligence in Oncology

In this first episode of Oncology Data Advisor’s new podcast series, “Exploring Artificial Intelligence in Cancer Care,” Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients’ probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost’s novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.

Predicting Immune-Related Adverse Events Through Machine Learning With Dr. Ofer Sharon of OncoHost

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.

Streamlining the Pathology Workflow Through AI: Waqas Haque and Leif Honda of TriMetis

In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.

Expanding Clinical Trial Access With Decentralization and Technology: Waqas Haque and Shaalan Beg

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. 

Check out the discussion to learn more about: 
•	Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies
•	Every Cure’s mission to unlock the potential of drugs that are already on the market
•	Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets
•	Barriers in drug repurposing, including clinical validation and eventual approval
•	The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research
•	How to develop efficient clinical trials without a large sample size
•	The future of AI-enabled drug discovery in oncology 
•	And more!

Every Cure: Unlocking Drug Potential With Artificial Intelligence With Waqas Haque and Tracey Sikora

This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. 

Check out the episode to hear more about: 
•	Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI
•	Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps
•	Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care
•	The efficacy of these solutions and how they can be used in the clinic
•	The lung cancer portfolio that Qure.ai showcased at ASCO
•	Other innovations coming down the pipeline
•	And more!

Qure.ai: Improving Early Lung Cancer Detection Through AI with Ranjana Devi and Waqas Haque, MD, MPH

Read the full article at: https://oncdata.com/travis-osterman-ai-informatics 

In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Travis Osterman, Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center, about the evolving role of health informatics in oncology. Their conversation spans training pathways, precision oncology, data standards, AI integrations, and the strategies to promote adoption in both academic and community practices.

Charting New Paths in Oncology Informatics With Travis Osterman, DO, and Waqas Haque, MD, MPH

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.

Listen now and earn 0.5 CME credit: bit.ly/49GyP5T

EXPIRING SOON! Diagnosis and Management of Dedifferentiated Liposarcoma

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: bit.ly/49NCaQu

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: bit.ly/405xEJO

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - https://bit.ly/4p7HRil
Monday, February 2 at 7:00 pm ET - https://bit.ly/495gnEd


Discovering Systemic Mastocytosis in Practice: A Webinar Preview With Lauren M. Madigan, MD

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRil
Monday, February 2 at 7:00 pm ET - bit.ly/495gnEd

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.

You can catch the live session on either of these dates:

Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0
Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Navigating HER2-Mutant NSCLC Pathology and Management: A Webinar Preview With Helena A. Yu, MD, and Maria Arcila, MD

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.

You can catch the live session on either of these dates:

Wednesday, January 8 at 5:00 pm ET: bit.ly/4iZxnA0
Monday, January 26 at 5:00 pm ET: bit.ly/4qALw9J

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Charting New Paths in Oncology Informatics With Travis Osterman, DO, and Waqas Haque, MD, MPH

Oncology Data Advisor®

Related tracks